PARPi are approved drugs in some cancer entities with BRCA1/2 genomic alterations (ovarian cancer, breast cancer, pancreatic cancer and prostate cancer10, 11, 12, 13, 14) and also in ovarian cancer characterized by HRD.15 This evidence concerns the gene BRCA1 and breast carcinoma.